Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,918,995

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.60 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Sector ETF report for IHE

Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

Style Box ETF report for FTCS

Merck (MRK) Gains But Lags Market: What You Should Know

Merck (MRK) closed at $87.42 in the latest trading session, marking a +0.63% move from the prior day.

Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Emergent (EBS) Initiates Study on Lassa Virus Vaccine Candidate

Emergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever.

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

Style Box ETF report for SCHD

Merck (MRK) Stock Moves -1.06%: What You Should Know

In the latest trading session, Merck (MRK) closed at $86.23, marking a -1.06% move from the previous day.

Benjamin Rains headshot

3 Stocks to Buy in September as the Market Falls and Rates Rise

Diving into three dividend-paying stocks that could be poised to help investors profit in September and beyond.

Company News for Aug 29, 2022

Companies in The News Are: AFRM,FTCH,SGEN,MRK,DELL

The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer

Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.

Iovance (IOVA) Starts Rolling BLA With FDA for Melanoma Therapy

Iovance (IOVA) starts a rolling BLA submission with the FDA seeking approval for its lead pipeline candidate in advanced melanoma patients. The filing is expected to be completed by fourth-quarter 2022.

Kinjel Shah headshot

Pharma Stock Roundup: NVS to Spin Off Sandoz; JNJ, MRK, ABBV's FDA Updates

Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.

Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

Bristol Myers (BMY) Up 14.6% YTD: Will the Performance Continue?

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue on label expansion of existing drugs.

Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead?

Lilly (LLY) expects to launch five new medicines by 2023-end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.

J&J (JNJ) Gets EU Nod for Multiple Myeloma Drug Tecvayli

J&J (JNJ) gets approval for Tecvayli (teclistamab) for the treatment of relapsed and refractory multiple myeloma. This marks the first approval for Tecvayli in any country.

AstraZeneca (AZN) Gets Japan Nod for Expanded Use of 3 Drugs

The Japanese Ministry of Health, Labour, and Welfare approved AstraZeneca's (AZN) three marketed drugs, Lynparza, Tagrisso and Ultomiris, for three different indications in Japan.

Phibro (PAHC) Q4 Earnings Miss Estimates, Sales Surpass

Phibro (PAHC) posts better-than-expected revenues for the fiscal fourth quarter, with robust growth across all segments.

Merck (MRK) Gets FDA Fast Track Tag for Anticoagulant Therapy

A phase II study is ongoing on Merck's (MRK) MK-2060 in people with end-stage renal disease receiving hemodialysis.

Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down

Medtronic (MDT) posts better-than-expected results for the fiscal first quarter and maintains earnings and sales outlook for the full year.

Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?

Smart Beta ETF report for FTCS

Kinjel Shah headshot

Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK

Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.

What's in the Cards for Medtronic (MDT) in Q1 Earnings?

Going by the industry-wide macro trend, we expect Medtronic (MDT) to once again report an adverse effect related to the global supply chain issues in fiscal Q1.

Zacks Market Edge Highlights: Merck, PepsiCo, Honeywell, Microsoft and PNC Financial

Merck, PepsiCo, Honeywell, Microsoft and PNC Financial have been highlighted in this Market Edge article.